Dr Christopher Wills
Teams and roles for Christopher Wills
Publication
Articles
- Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium, et al., 2025. Genetic modifiers of somatic expansion and clinical phenotypes in Huntington’s disease highlight shared and tissue-specific effects. Nature Genetics 57 , pp.1426-1436. (10.1038/s41588-025-02191-5)
- Wills, C. et al. 2025. Relationship between inherited genetic variation and survival from colorectal cancer stratified by tumour location. Scientific Reports 15 2423. (10.1038/s41598-024-77870-0)
- Wills, C. et al. 2023. Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer. Genes Chromosomes and Cancer 62 (6), pp.332-341. (10.1002/gcc.23133)
- Wills, C. et al. 2023. Relationship between 233 colorectal cancer risk loci and survival in 1,926 patients with advanced disease. BJC Reports 1 2. (10.1038/s44276-023-00003-z)
- Watts, K. et al. 2022. Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. International Journal of Cancer 151 (6), pp.957-966. (10.1002/ijc.34046)
- Wills, C. et al. 2021. Genome-wide search for determinants of survival in 1,926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. European Journal Of Cancer 159 , pp.247-258. (10.1016/j.ejca.2021.09.047)
- Watts, K. et al. 2021. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. International Journal of Cancer 149 (9), pp.1713-1722. (10.1002/ijc.33739)
Thesis